BIO-Europe Spring Presenting Companies 2023
BiondVax Pharmaceuticals Ltd
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative VHH-antibody (NanoAb) pipeline in collaboration with Max Planck Institute for Multidisciplinary Sciences (MPI) and the University Medical Center Göttingen, Germany (UMG).